Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.27%
#2 aelf aelf +23.11%
#3 Bitway Bitway +14.16%
#4 Decred Decred +12.61%
#5 Pons Pons +9.42%
#6 TRIA TRIA +8.74%
#7 Wibx Wibx +8.12%
#8 AtomOne AtomOne +7.63%
#9 DexNet DexNet +7.55%
#10 Status Status +6.90%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc.

OTLC
Rangering i aksjer #30394
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage... Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Aksjekurs
$0.03834
Sist synkronisert: 2026-08-18
Markedsverdi
$17.01M
Endring (1 dag)
-4.15%
Endring (1 år)
-24.82%
Land
US
Handel Oncotelic Therapeutics, Inc. (OTLC)

Kategori

Healthcare
Inntekter for Oncotelic Therapeutics, Inc. (OTLC)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Oncotelic Therapeutics, Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Oncotelic Therapeutics, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE